[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Institut de Cancérologie de Lorraine\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":211},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,47,74,100,130,153,183],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100618067","efficacy-of-the-maeva-program-meditation-acceptance-and-commitment-to-values-among-patients-treated-for-breast-cancer-100618067",false,"NCT07326800","Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cancer.","Efficacy of the MAEva Program (Meditation, Acceptance, and Commitment to Values) Among Patients Treated For Breast Cancer : a Randomized, Multicenter Clinical Trial","MAEva-MCT","Inclusion Criteria:\n\n* Patients with non-metastatic breast cancer,\n* Patients who are able and willing to follow all study procedures in accordance with the protocol,\n* Patients who have understood, signed, and dated the consent form,\n* Patients who are affiliated with the social security system,\n* Patients who are able to remain seated during the 1.5-hour sessions.\n\nExclusion Criteria:\n\n* Patients with metastatic cancer,\n* Presence of an acute psychiatric disorder: acute depression, unstable bipolar disorder, psychotic disorder (delusions, hallucinations), etc.\n* Presence of recurrent uncontrolled panic attacks (particularly related to hypochondriacal concerns),\n* Insufficient attentional resources for meditation: major attention, memory, or reasoning disorders,\n* Presence of cognitive and neurocognitive disorders and deficits,\n* Presence of deafness,\n* Current participation in another mindfulness program,\n* Persons deprived of their liberty or under guardianship (including curatorship),\n* Inability to undergo medical monitoring for the trial for geographical, social, or psychological reasons.","FEMALE","18 Years",{"count":20,"type":21},190,"ESTIMATED","INTERVENTIONAL",[24],"NA","The MAEva program combines Acceptance and Committment Therapy (ACT) and mindfulness practices. It is an open and circular intervention, in three sessions (Mindfulness, Acceptance, and Commitment to values). It is designed for cancer patients and was the subject of an initial study that explored its feasibility and acceptability, as well as the initial results on psychological well-being.\n\nThis randomized, multicenter clinical trial is necessary to demonstrate the efficacy of the MAEva program compared to a discussion group with non metastatic breast cancer patients.\n\nPatients will be included and randomized into two arms:\n\n* In the first arm, patients will have the opportunity to participate in the MAEva program for nine consecutive weeks.\n* and the second arm patients will have the opportunity to participate in a discussion group for nine consecutive weeks.\n\nThe patients will be able to attend one session per week for nine consecutive weeks.\n\nQuantitative assessments of quality of life, symptoms of stress, anxiety, and depression, as well as psychological flexibility, will be conducted before the first session, after 3 weeks, 9 weeks, and 12 weeks.\n\nAlso, a qualitative analysis will be conducted based on satisfaction questionnaire and a semistructured interview performed after the end of the program. The interview analysis will described the extent to which the intervention is adapted to the realities on the ground and the needs of the target population. It will enable to identify how patients appropriate the psychological flexibility processes taught in the program in relation to the conceptual framework of ACT therapy (i.e., contact with the present moment, self-as-context, acceptance, defusion, values, and committed action) and integrate them into their daily lives.",[27],"Non Metastatic Breast Cancer",[29,30,31,32,33],"Cancer","MAEva program","Mindfulness","Acceptance and commitment therapy","Quality of life","RECRUITING","2026-04-13",{"date":37,"type":38},"2026-04-16","ACTUAL",{"date":40,"type":38},"2026-02-16",{"date":42,"type":21},"2029-02-16",{"name":44,"class":45},"Institut de Cancérologie de Lorraine","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":51,"acronym":52,"eligibilityCriteria":53,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":22,"phases":56,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":46},"100558513","guided-digital-self-hypnosis-solution-for-managing-hot-flashes-in-patients-undergoing-adjuvant-hormone-therapy-100558513","NCT06552091","Guided Digital Self-Hypnosis Solution for Managing Hot Flashes in Patients Undergoing Adjuvant Hormone Therapy","HYBOU","Inclusion Criteria:\n\n* Adult patient,\n* WHO ≤ 2,\n* Patient who is premenopausal, perimenopausal, or postmenopausal at diagnosis,\n* Patient being treated for non-metastatic breast cancer,\n* Ongoing adjuvant endocrine therapy, with or without concomitant anti-CDK 4\u002F6 targeted therapy,\n* Patient reporting at least 50 hot flashes per week or at least 7 hot flashes per day\n* Patient has a computer device capable of accessing the self-hypnosis program link,\n* Information provided and informed consent signed,\n* Patient affiliated with the social security system.\n\nExclusion Criteria:\n\n* Male,\n* Patient with hearing impairments,\n* Patient with psychotic and\u002For cognitive disorders As assessed by the clinician,\n* Patient who does not understand the French language,\n* Patient not diagnosed with non-metastatic breast cancer,\n* Patient not undergoing anti-aromatase treatment,\n* Patient reporting fewer than 50 hot flashes per week or fewer than 7 hot flashes per day,\n* Prior participation in a hypnosis or self-hypnosis program before inclusion,\n* Patient participating in a therapeutic program related to hot flashes,\n* Patient already included in another therapeutic trial on the same topic,\n* Patient already included in another therapeutic trial with an experimental drug,\n* Pregnant or breastfeeding woman,\n* Patient deprived of liberty (including guardianship and curatorship).",{"count":55,"type":21},76,[24],"Patients treated for breast cancer with hormone therapy (HT) suffer from hot flashes. This side effect impacts treatment adherence. Indeed, approximately 50% of women take less than 80% of the prescribed dose, and up to 50% abandon their treatment before the fifth year of prescription, significantly increasing the risk of recurrence. Moreover, these hot flashes strongly impact the quality of life. According to the CANTO study, these hot flashes can persist up to two years after diagnosis, affecting social relationships, return to work, and physical and mental health.\n\nSome side effects resulting from HT (sleep disturbances, fatigue, hot flashes) could be alleviated by a non-pharmacological approach involving the patient.\n\nOur hypothesis is that a non-pharmacological solution, such as the use of self-hypnosis, could reduce hot flashes and the side effects related to HT or the perception thereof in patients treated for breast cancer. Consequently, this could improve the quality of life and lead to better treatment adherence.\n\nThe principal objective is to evaluate the effect of daily guided self-hypnosis sessions in reducing hot flashes in patients with non-metastatic breast cancer receiving anti-aromatase hormone therapy.\n\nThe secondary objectives are to evaluate :\n\n* Patient adherence to guided self-hypnosis via a digital solution\n* Quality of life\n* Sleep quality\n* Satisfaction with care\n* Usability of the digital tool\n\nThe originality of this clinical trial is the proposal of self-hypnosis sessions over three weeks with three different themes using a digital solution.",[59],"Breast Cancer Female",[61,62,63,64,65],"breast cancer","non-metastatic","hormone therapy","hot flashes","self-hypnosis","2026-02-12",{"date":68,"type":38},"2026-02-17",{"date":70,"type":38},"2024-10-17",{"date":72,"type":21},"2027-02-17",{"name":44,"class":45},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":78,"acronym":79,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":81,"targetDuration":83,"studyType":84,"phases":4,"briefSummary":85,"conditions":86,"keywords":88,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":92,"lastUpdatePostDateStruct":93,"startDateStruct":95,"completionDateStruct":97,"leadSponsor":99,"locationsCount":46},"100605687","mon-parcours-de-vie-localized-breast-cancer-announcement-support-information-on-the-disease-and-treatments-pilot-study-to-assess-the-value-of-written-information-documents-100605687","NCT07165756","\"Mon Parcours de Vie\" Localized Breast Cancer: Announcement, Support, Information on the Disease and Treatments. Pilot Study to Assess the Value of Written Information Documents.","MaVie","Inclusion Criteria:\n\n* Patient with localized breast cancer consulting for medical treatment (chemotherapy+\u002F- immunotherapy+\u002Fanti-HER2 targeted therapy)\n* Diagnosis of invasive breast cancer for which there is an indication for local and medical treatment.\n* WHO ≤ 1\n* Patient has understood, signed and dated the consent form\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Patient with metastatic breast cancer\n* History of other cancer\n* Patient unable to read or speak French\n* Persons deprived of liberty or under guardianship (including curatorship).",{"count":82,"type":21},60,"14 Days","OBSERVATIONAL","Since late 2019, the French association \"MON PARCOURS DE VIE\" has developed books donated by caregivers at cancer centers in France. These documents are available online: https:\u002F\u002Fwww.monparcoursdevie.fr\u002F. They are highly acclaimed by women suffering from the breast cancer, as well as by caregivers. Four volumes have been written: 'Metastatic breast cancer', 'Localized breast cancer', 'Preserving my well-being', 'After breast cancer', and finally 'Breast cancer, support and accompaniment'.\n\nThe aim in writing these information brochures is to provide clear, concise, useful information, with pedagogy, gentleness, benevolence, humility, cheerfulness, imagination, simplicity and an innovative presentation. These documents are a new and innovative method of providing information, delivered by caregivers who work with women suffering from breast cancer. It extends the human support so necessary in this disease.\n\nIt seemed important to us to evaluate, through a clinical study, the impact of the written documents \"Mon Parcours de Vie\" - volume 2: Breast cancer and volume 3: Preserving my well-being, concerning the announcement of a localized breast cancer in the initial management for the first time in the breast pathway. The objectives of the clinical study are to evaluate the acceptability and impact of these two written information documents on anxiety generated by the announcement of cancer and treatment.",[87],"Localized Breast Cancer",[89,90,91],"Announcement of cancer and treatment","Breast cancer","Information documents","2025-12-19",{"date":94,"type":38},"2025-12-22",{"date":96,"type":38},"2025-09-09",{"date":98,"type":21},"2026-11-01",{"name":44,"class":45},{"id":101,"slug":102,"hasResults":11,"nctId":103,"briefTitle":104,"officialTitle":105,"acronym":106,"eligibilityCriteria":107,"healthyVolunteers":11,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":109,"targetDuration":4,"studyType":22,"phases":111,"briefSummary":112,"conditions":113,"keywords":116,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":122,"lastUpdatePostDateStruct":123,"startDateStruct":125,"completionDateStruct":127,"leadSponsor":129,"locationsCount":5},"100552898","prognostic-value-of-measuring-ctdna-in-a-cohort-of-patients-with-stage-iii-and-iv-upper-aero-digestive-tract-uadt-cancer--treated-with-curative-radiotherapy-with-or-without-concomitant-treatment-100552898","NCT06479070","Prognostic Value of Measuring CtDNA in a Cohort of Patients With Stage III and IV Upper Aero-digestive Tract (UADT) Cancer , Treated With Curative RADiOtherapy With or Without Concomitant Treatment.","Prognostic Value of Measuring Circulating Tumor DNA in a Cohort of Patients With Stage III and IV UADT Cancer, Treated With Curative RADiOtherapy With or Without Concomitant Treatment.","CIRADOR","Inclusion Criteria\n\n* OMS 0 to 2;\n* Patient suffering from UADT squamous cell carcinoma, newly diagnosed and histologically proven, regardless of the p16 protein status, naïve to any treatment for this cancer;\n* Non-metastatic cancer of stages III (N1), IVa (N1 minimum) or IVb;\n* Cancer localized in the oral cavity, larynx, oropharynx, hypopharynx and maxillary sinus;\n* Patient for whom treatment with curative radiotherapy associated or not with concomitant treatment (Cisplatin or Cetuximab) has been validated in a multidisciplinary consultation meeting (RCP);\n* Patient capable and willing to follow all study procedures in accordance with the protocol;\n* Patient having understood, signed and dated the consent form communicated on the day of inclusion;\n* Patient affiliated to the social security system.\n\nExclusion Criteria:\n\n* Minor patient;\n* Cancer located in the cavum, ethmoidal sinus, salivary glands and skin (cutaneous squamous cell carcinoma);\n* Patient already treated for UADT tumor;\n* Patient treated with immunotherapy;\n* Patient who has already had cancer within 5 years (cancer other than in the UADT sphere);\n* OMS \\> 2;\n* Contraindication to radiotherapy treatment associated or not with concomitant treatment;\n* Patient already included in another therapeutic trial;\n* Metastatic disease (stage IVc);\n* Pregnant woman, who may be pregnant, or currently breastfeeding;\n* Persons deprived of liberty or under guardianship (including curatorship).","ALL",{"count":110,"type":21},188,[24],"Squamous cell carcinomas of the upper aero-digestive tract (SCC-UADT) represent the seventh cause of cancer and affect approximately 600,000 patients per year worldwide. The majority of UADT cancers are diagnosed at an advanced stage (70.3% at stage III and IV) and less than 60% of these patients are free of the disease at 3 years, despite aggressive multimodal local treatment by surgery and \u002For radiochemotherapy. The average progression-free survival (PFS) at 2 years varies between 45 and 60% depending on the studies. Tumor recurrence is most often incurable. To our knowledge, no study has demonstrated the benefit of early evaluation of the rate of decrease in ctDNA at 1 month after the end of radiotherapy alone or associated with concomitant treatment, as a predictive factor of PFS in UADT squamous cell carcinomas regardless of their HPV status. The main objective of this study is to evaluate the value of measuring the quantity of circulating tumor DNA (ctDNA) at 1 month post-treatment as a predictive factor for PFS at 24 months.",[114,115],"SCC - Squamous Cell Carcinoma","Upper Aero-digestive Tract (UADT) Neoplasm",[117,118,119,120,121],"Squamous Cell Carcinoma","upper aero-digestive trac tumor","Ct DNA","Radiotherapy","Head and neck cancer","2025-12-18",{"date":124,"type":38},"2025-12-24",{"date":126,"type":38},"2024-09-30",{"date":128,"type":21},"2029-09-30",{"name":44,"class":45},{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":134,"acronym":135,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":46},"100511176","comparative-study-of-the-quality-of-life-of-patients-suffering-from-ototoxicity-due-to-chemotherapy-based-on-platinum-salts-fitted-with-a-hearing-aid-compared-to-those-not-fitted-100511176","NCT05936034","Comparative Study of the Quality of Life of Patients Suffering From OTOTOXICITY Due to Chemotherapy Based on Platinum Salts Fitted With a Hearing Aid Compared to Those Not Fitted.","PROTOTOX","Inclusion Criteria:\n\n* Adult patient\n* Patient currently undergoing treatment with platinum-based chemotherapy and suffering from hypoacusia consistent with the treatment or presenting a worsening of already existing hypoacusis consistent with the start of treatment with platinum-based chemotherapy\n* Patient whose hypoacusis is confirmed by the audiometric test\n* Patient able and willing to follow all study procedures in accordance with the protocol.\n* Patient having understood, signed and dated the consent form\n* Patient affiliated to the social security system\n\nExclusion Criteria:\n\n* Pregnant or breastfeeding woman\n* Persons deprived of liberty or under guardianship (including curatorship)\n* Impossibility of submitting to medical monitoring of the trial for geographical, social or psychological reasons\n* Patient with a contraindication to wearing hearing aids\n* Patient already fitted\n* Patient already included in a protocol including an experimental molecule\n* Patient who has not started treatment with platinum-based chemotherapy\n* Patient presenting only tinnitus without hearing loss",{"count":138,"type":21},52,[24],"There are many undesirable effects associated with platinum-based cancer treatments (renal failure, anaemia, etc.). Their administration also leads to neurosensory problems such as ototoxicity, tinnitus and reduced hearing acuity. According to a the French survey (2018), 39.7% of people suffer from hearing problems due to cancer treatments, five years after a cancer diagnosis.\n\nImproving side effects such as hypoacusis and tinnitus can significantly improve patients' quality of life and adherence to treatment. Many clinical trials proposed a medicinal solution to patients receiving platinum-based cancer treatments but none has led to a consensus on management.\n\nThe aim of the study is to offer patients receiving platinum-based chemotherapy and suffering from hearing problems a hearing aid to improve their quality of life.",[29,142,143,144],"Ototoxicity, Drug-Induced","Quality of Life","Hearing Disorders","2025-11-21",{"date":147,"type":38},"2025-11-28",{"date":149,"type":38},"2024-01-04",{"date":151,"type":21},"2028-07-04",{"name":44,"class":45},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":161,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":171,"overallStatus":175,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":177,"startDateStruct":179,"completionDateStruct":180,"leadSponsor":182,"locationsCount":4},"100599822","impact-of-anesthesia-alarm-volume-on-mental-workload-in-surgical-trainees-100599822","NCT07089485","Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees","Impact of Anesthesia Alarm Volume on Mental Workload in Surgical Trainees: A Randomized Pilot Simulation Study","ASLEC02","Inclusion Criteria:\n\n* Surgical residents or experienced surgeons;\n* Surgeons with normal hearing;\n* Surgeons capable of performing surgical sutures (regardless of skill level);\n* Surgeons able and willing to follow all study procedures according to the protocol;\n* Surgeons who have understood, signed, and dated the informed consent form provided on the day of enrollment.\n\nExclusion Criteria:\n\n* Surgeons undergoing beta-blocker treatment;\n* Surgeons with known cardiac pathology;\n* Surgeons who do not consent to participate in the study;\n* Surgeons with known hearing problems;\n* Surgeons who fail the hearing test;\n* Surgeons who worked on-call or night shifts during the night before the evaluation day.\n* Surgical trainees at the Lorraine Cancer Institute.\n* Adults under legal protection (guardianship, curatorship, or legal supervision);Persons deprived of liberty;Pregnant or breastfeeding women.",true,{"count":163,"type":21},26,[24],"Noise in hospital environments, particularly in operating rooms, poses challenges to both patient comfort and healthcare professionals' performance. Among the sources of noise, anesthesia monitoring alarms are essential for patient safety, yet no clear guidelines exist regarding their optimal sound level. Excessive alarm volume may increase distraction and cognitive load, especially for surgical trainees, potentially impairing their focus and performance during procedures. This randomized pilot interventional study aims to evaluate the impact of anesthesia alarm sound intensity on the mental workload of surgical trainees performing simulated surgeries. Participants will be randomly assigned to conditions with either an optimized alarm volume or a higher standard volume during simulated tasks. Cognitive load will be assessed using objective physiological measures such as heart rate variability and pupillometry, as well as subjective evaluations with tools like the NASA-TLX and SURG-TLX scales. The primary goal is to determine whether an optimized alarm sound level can reduce cognitive strain without compromising vigilance required for patient safety. Findings from this study are expected to provide evidence-based recommendations for auditory ergonomics in operating rooms, ultimately improving working conditions for surgical teams and enhancing both training and patient safety.",[167,168,169,170],"Surgical Procedures","Noise","Hearing Disorder","Mental Workload",[172,173,174],"Noise\u002Fadverse effects","Cognition Disorders","Surgical procedures","NOT_YET_RECRUITING","2025-09-22",{"date":178,"type":38},"2025-09-25",{"date":178,"type":21},{"date":181,"type":21},"2026-09-26",{"name":44,"class":45},{"id":184,"slug":185,"hasResults":11,"nctId":186,"briefTitle":187,"officialTitle":188,"acronym":189,"eligibilityCriteria":190,"healthyVolunteers":11,"sex":108,"minAge":18,"maxAge":4,"enrollmentInfo":191,"targetDuration":4,"studyType":22,"phases":193,"briefSummary":194,"conditions":195,"keywords":198,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":176,"lastUpdatePostDateStruct":203,"startDateStruct":205,"completionDateStruct":207,"leadSponsor":209,"locationsCount":210},"100584053","spinal-palliation-in-irradiation-for-neoplastic-analgesia-and-life-quality-100584053","NCT06884332","Spinal Palliation in Irradiation for Neoplastic Analgesia and Life Quality","Étude de Non infériorité Sur l'Impact de la Diminution Des Volumes d'Irradiations vertébraux en Cas d'Irradiation Palliative Rachidienne métastatique Osseuse Sur l'efficacité Antalgique","SPINAL","Inclusion Criteria:\n\n* Patient with bone pain related to at least 1 or more bone metastases of spinal location, contiguous or not, cervical (excluding C1), thoracic, lumbar or sacral up to and including S2; a patient can be included even if he or she is irradiated concomitantly or not for analgesic purposes on another non-spinal bone metastatic site. Bone lesions are objective on an imaging examination less than 3 months old: CT and\u002For MRI and\u002For PET and\u002For bone scintigraphy;\n* Patient with at least moderate pain with EN ≥ 5;\n* Patient on analgesic drug treatment for at least 7 days or poor tolerance of analgesics;\n* Patient irradiated for palliative analgesic purposes. Post-cementoplasty irradiation is possible; an extension to the soft tissues is not a contraindication to inclusion;\n* Patient with a validated palliative bone irradiation plan: 8 Gy \u002F 1 fr or 20 Gy \u002F 5 fr;\n* Patient with planning only in static IMRT, arc therapy or helical tomotherapy;\n* Patient with a primary cancer or a haemopathy;\n* Patient currently undergoing or not a specific oncological systemic treatment, left to the discretion of the investigating physician;\n* Patient currently undergoing or not a treatment with bisphosphonates and denosumab, left to the discretion of the investigating physician;\n* WHO ≤ 2;\n* Patient with a life expectancy ≥ 3 months;\n* Patient able and agreeing to follow all study procedures in accordance with the protocol;\n* Patient having understood, signed and dated the consent form;\n* Patient affiliated to the social security system.\n\nExclusion Criteria:\n\n* Pediatric patient;\n* Patient undergoing stereotaxic irradiation;\n* Patient undergoing oligometastatic disease;\n* Patient undergoing re-irradiation unless the dose is not limiting to OARs;\n* Patient treated with RT2D (conventional 2-dimensional radiotherapy) or RT3D (conventional 3-dimensional radiotherapy);\n* Patient with MESCC (metastatic epidural spinal cord compression) except for a Bilsky grade \\\u003C 1b;\n* Patient who does not have a means of responding to online questionnaires;\n* Patient and their entourage who cannot read or express themselves in French;\n* Visually impaired patient;\n* Patient already included in another therapeutic trial with an experimental molecule;\n* Persons deprived of liberty or under guardianship (including curatorship).\n* Pregnant woman, likely to be pregnant, or breastfeeding",{"count":192,"type":21},598,[24],"The goal of this clinical trial is to assess the impact of reducing the volume of palliative metastatic bone irradiation on analgesic effectiveness at day 30 and to evaluate the efficiency of telemonitoring in identifying patients who could benefit from Patient-Reported Outcomes (PROs) and require care.\n\nThese objectives will be addressed in a multicenter, randomized, prospective study with two arms:\n\nA standard arm with spinal irradiation without sparing the adjacent vertebrae. An experimental arm with spinal irradiation sparing the adjacent vertebrae. The results will determine whether reducing the irradiated volume can maintain effective pain relief while minimizing side effects.",[196,197],"Bone Metastasis","Oncology Pain",[199,200,201,202],"Bone metastasis","Irradiation","Palliative","Analgesic",{"date":204,"type":38},"2025-09-23",{"date":206,"type":38},"2025-07-02",{"date":208,"type":21},"2029-01-02",{"name":44,"class":45},4,""]